These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9489519)

  • 1. Modulating the immune response in demyelinating diseases.
    Hughes R
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148. PubMed ID: 9489519
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
    Créange A; Bélec L; Clair B; Degos JD; Raphaël JC; Gherardi RK
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):162-5. PubMed ID: 9489524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
    Rees JH
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148-9. PubMed ID: 9489520
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins.
    Briellmann RS; Nydegger UE; Sturzenegger M; Fierz L; Hess CW; Hauser SP
    Eur Neurol; 1998; 39(3):190-1. PubMed ID: 9605400
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome?
    Weinstein R
    J Clin Apher; 1995; 10(3):150-7. PubMed ID: 8582898
    [No Abstract]   [Full Text] [Related]  

  • 6. A practical approach to the use of intravenous immunoglobulin in neurological disease.
    Wills AJ; Unsworth DJ
    Eur Neurol; 1998; 39(1):3-8. PubMed ID: 9476717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future developments in the treatment of immune-mediated polyneuropathies.
    van der Meché FG; van Doorn PA
    Eur Neurol; 1997; 38(3):230-7. PubMed ID: 9363836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational therapy of Guillain-Barré syndrome.
    Samman I; Wöhrle JC; Hennerici M
    Lancet; 1998 Mar; 351(9104):753-4. PubMed ID: 9504543
    [No Abstract]   [Full Text] [Related]  

  • 9. Root stimulation improves the detection of acquired demyelinating polyneuropathies.
    Menkes DL; Hood DC; Ballesteros RA; Williams DA
    Muscle Nerve; 1998 Mar; 21(3):298-308. PubMed ID: 9486858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-D immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy.
    Vermeulen M; van Schaik IN; Brand A
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):383-4. PubMed ID: 7897433
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic demyelinating polyneuropathy in pregnancy treated with intravenous immunoglobulin.
    Nwosu EC; Tandon S; Breeze C; Enevoldson TP; Khaleeli AA
    Br J Obstet Gynaecol; 1999 Feb; 106(2):174-6. PubMed ID: 10426685
    [No Abstract]   [Full Text] [Related]  

  • 12. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyck PJ; Litchy WJ; Kratz KM; Suarez GA; Low PA; Pineda AA; Windebank AJ; Karnes JL; O'Brien PC
    Ann Neurol; 1994 Dec; 36(6):838-45. PubMed ID: 7998769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomodulator therapy of chronic inflammatory demyelinating polyradiculoneuropathy].
    Jakobsen J; Krarup C
    Ugeskr Laeger; 1991 Aug; 153(32):2235-7. PubMed ID: 1882475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational therapy of Guillain-Barré syndrome.
    Berciano J
    Lancet; 1998 Mar; 351(9104):754-5. PubMed ID: 9504544
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy; different beneficial effects and their correlation to the clinical features.
    Kumazawa K; Sobue G; Yamamoto K; Kitano M; Nakamura S; Kato K; Mitsuma T
    Intern Med; 1995 Jun; 34(6):537-41. PubMed ID: 7549138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases.
    Stangel M; Toyka KV; Gold R
    Arch Neurol; 1999 Jun; 56(6):661-3. PubMed ID: 10369303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Thompson N; Choudhary P; Hughes RA; Quinlivan RM
    J Neurol; 1996 Mar; 243(3):280-5. PubMed ID: 8936360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.
    Vera-Ramirez M; Charlet M; Parry GJ
    Neurology; 1992 Aug; 42(8):1636-7. PubMed ID: 1641167
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyck PJ; Daube J; O'Brien P; Pineda A; Low PA; Windebank AJ; Swanson C
    N Engl J Med; 1986 Feb; 314(8):461-5. PubMed ID: 3511382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.
    Choudhary PP; Hughes RA
    QJM; 1995 Jul; 88(7):493-502. PubMed ID: 7633875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.